| Empagliflozin, Linagliptan and Metformin Hydrochloride | Boehringer Ingelheim | ||
| 5mg/2.5mg/1 g,10mg/5mg/1g,12.5mg/5mg/1g,25mg/5mg/1 |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
| None | None | ||
| TRIJARDY XR is a combination of empagliflozin, linagliptin, and metformin hydrochloride (HCl) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus | |||
|
Yes
| |||
| Trijardy XR | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ****** | *** ********* | *** ********* | ******* | *** ********* | *** ********* | *** ********* | ******* | *** ********* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ***** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | **** ** ***** **, **** | **** ** ***** **, **** | **** ** ***** **, **** | **** ** ***** **, **** | **** ** ***** **, **** | **** ** ***** **, **** | *** ********* | **** ** *** **, **** |
| ***-** ********* ******** **** * ******* ************ *****, ******* ********** **** ************, ***** *** *** ******* *** ***** *********** | ************** ***********, ******* *** ******** *** **** ******* | ************** ***********, ******* *** ******** *** **** ******* | ************** ************ | ************** ***********, ******* *** ******** *** **** ******* | ****** ****** ** ******* ******* ********* ** ********* **********-******* **** ****** ***** | *-[*-*****-*********-*-**]-*********, *** *********** ******* *** ***** *** ** ************** ************ | **************-*********** ****** ***********, *********** ********** **** *********, ***** *** *** ******* *** ***** *********** | *********** **** ** *-******-*-(β-*-************-*-**)-*-[*-((*)-***************-*-*****)-******]-*******, * ****** *** *** *********** *** *** *** ******* *** ********* *********** | *-[*-*****-*********-*-**]-*********, *** *********** ******* *** ***** *** ** ************** ************ | *-[*-*****-*********-*-**]-*********, *** *********** ******* *** ***** *** ** ************** ************ | ************** *********** ********** * **************-*********** ******* ******** | ******* *** *** *********** ** ****** *-(*-**************-*-**)-********* | ***-** ********* ******** **** * ******* ************ *****, ******* ********** **** ************, ***** *** *** ******* *** ***** *********** | ***-** ********* ******** **** * ******* ************ *****, ******* ********** **** ************, ***** *** *** ******* *** ***** *********** | ************** ***********, ******* *** ******** *** **** ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| *** ****** | ***\ ********* | *** **, **** | ******* | **** | ******* *** **** *** *** **** |
| ***** | **\ ** | *** **, **** | ******* | ********* ******** | ******* *** **** *** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|